Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 8, 2009, Pages 981-986

  Crandall, Mark A ^a   Horne, Benjamin D ^b,c   Day, John D ^b   Anderson, Jeffrey L ^b,c   Muhlestein, Joseph B ^b,c   Crandall, Brian G ^b   Weiss, J Peter ^b   Osborne, Jeffrey S ^b   LappÉ, Donald L ^b,d   Bunch, T Jared ^b  

^a MAYO CLINIC   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Salt Lake City UT   (United States)

Author keywords

Atrial fibrillation; Clinical; Electrophysiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RISK; RISK FACTOR; SCORING SYSTEM; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ATRIAL FIBRILLATION; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; RISK ASSESSMENT; RISK FACTORS; STROKE; SURVIVAL ANALYSIS; SURVIVAL RATE; UNITED STATES;

EID: 68449093978     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02427.x     Document Type: Article

References (24)

1. Page RL. Clinical practice. Newly diagnosed atrial fibrillation. N Engl J Med 2004 351 : 2408 2416.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002 113 : 359 364.
3. Vidaillet H, Granada JF, Chyou PH, Maassen K, Ortiz M, Pulido JN, Sharma P, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002 113 : 365 370.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001 285 : 2864 2870.
5. Anderson JL, Allen Maycock CA, Lappe DL, Crandall BG, Horne BD, Bair TL, Morris SR, et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 2004 94 : 1255 1259.
6. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998 136 : 792 803.
7. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003 163 : 936 943.
8. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA 2003 290 : 2685 2692.
9. Khumri TM, Idupulapati M, Rader VJ, Nayyar S, Stoner CN, Main ML. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. Am J Cardiol 2007 99 : 1733 1736.
10. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 51 : 810 815.
11. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 : e257 e354.
12. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: Mechanisms and clinical implications. Pacing Clin Electrophysiol 1996 19 : 95 106.
13. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, et al., CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular dysfunction: Results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006 47 : 1997 2004.
14. Bunch TJ, Day JD, Olshansky B, Stolen KQ, Mullin CM. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009 6 : 2 8.
15. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004 109 : 1509 1513.
16. Freudenberger RS, Wilson AC, Kostis JB. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol 2007 100 : 247 252.
17. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000 356 : 1789 1794.
18. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 1840.
19. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
20. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003 41 : 1690 1696. (Pubitemid 36584236)
21. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004 126 : 476 486.
22. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 358 : 2667 2677.
23. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 2001 104 : 292 296.
24. Reiffel JA. A contemporary look at classic trials in atrial fibrillation: What do they really show and how might they apply to future therapies? Am J Cardiol 2008 102 : 3H 11H.